Key features of our bladder cancer PDO panel

  • A comprehensive collection of 10 bladder cancer PDOs, sourced from both treatment-naïve and pre-treated patients
  • Rigorously characterized, with readily available DNA and RNA sequencing data
  • Diverse models encompassing both non-invasive and advanced muscle-invasive bladder cancer
  • Benchmarked against standard-of-care (SoC) treatments such as Erdafitinib and Gemcitabine
  • Representing pivotal bladder cancer drivers such as FGFR3, KMT2C, KMT2D, TP53, and ERBB2 and many others
  • Access to invaluable clinical data, including histology data, tumor classification, and patient profiles

explore our panel

Advanced screening capabilities

  • ATP-based cell-viability assay, with GR50 readouts
  • 3D assay format, compatible with both 96- and 384-well plate layouts.
  • Test up to 10 compounds in triplicate
  • 10-point dose-response curves per drug
  • A panel of 10 models, each designed to represent key bladder cancer drivers

Unlock the potential of bladder cancer research with our PDO screen panel

enroll now


Have any questions?

contact us